Abstract: TH-PO1056
Cancer Development and Mortality Differences in Patients with Glomerulonephritis After Renal Biopsy
Session Information
- Glomerular Diseases: Epidemiology, Mechanisms, Complications, Outcomes
November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1203 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Ryu, Hyunjin, Seoul National University Hospital, JongNo-Gu, seoul, Korea (the Republic of)
- Ryu, Ji Young, Seoul National University Bundang Hospital, SungNam, Korea (the Republic of)
- Kim, Kipyo, Seoul National University Bundang Hospital, SungNam, Korea (the Republic of)
- Kim, Sejoong, Seoul National University Bundang Hospital, SungNam, Korea (the Republic of)
- Na, Ki Young, Seoul National University Bundang Hospital, SungNam, Korea (the Republic of)
- Chae, Dong-Wan, Seoul National University Bundang Hospital, SungNam, Korea (the Republic of)
- Chin, Ho Jun, Seoul National University Bundang Hospital, SungNam, Korea (the Republic of)
Group or Team Name
- Korean GlomeruloNephritis Study Group
Background
This retrospective cohort study was conducted to evaluate the cancer incidence in renal biopsy proven glomerulonephritis (GN) patients during the follow ups and to find out the mortality differences according to cancer occurrence.
Methods
This is a retrospective cohort study conducted in a single center. Among 1,600 patients who have underwent renal biopsy between 2003 and 2017, in Seoul National Bundang Hospital, after excluding 611 patients who are inappropriate for the analysis, a total 929 adult patients were analyzed. (Figure) Baseline clinical characteristics, renal biopsy result and types and dose of immunosuppressant usages during the follow-up were collected. Incidence of cancer was censored when the 1st cancer was diagnosed and the mortality was detected during the follow ups.
Results
During the mean 52.4 months (range 1.0-166.7 months) of follow-up, total 49 cases were newly diagnosed as cancer. When we compared the clinical characteristics between the patients who developed cancer and the others, cancer patient were older and had higher prevalence of coronary heart disease and diabetes, lower level of hemoglobin and higher immunosuppressant usage. When the multivariate Cox regression analysis were conducted to find out the risk factors for the cancer development, membranous nephropathy (MN) pathologic diagnosis showed hazard ratio of 2.6 (95% CI 1.32-5.30) after adjusting age, gender, clinical parameters and usage of immunosuppressant. In the subgroup analyais among MN patients, age was the only significant risk factor for the cancer development afte adjusting other confouders. During the follow up, total 86 patients died. In the MN patients , the patients who developed cancer had higher mortality with hazard ratio of 5.95 (95% CI 1.36-26.09, p=0.018) compared to MN patients without cancer, when the multivariate Cox’s proportional hazard model were conducted.
Conclusion
Among the GN population without concurrent cancer, patients with MN should be aware of cancer developments during the follow up, since they have significant higher risk of cancer devolvement and which results in higher mortality rate.